CARTITUDE-1 Update Discussion
Panelists discuss how the durability of response and long-term minimal residual disease (MRD) negativity in a subset of patients supports redefining treatment end points and cure in multiple myeloma.
The study’s durability data are groundbreaking, with one-third of patients experiencing long-term MRD-negative complete remission. These findings support the argument that multiple myeloma may now be curable in select patients.
For the first time, clinicians have a framework to consider discontinuation of maintenance therapy in patients who achieve deep, durable responses. This has significant implications for improving quality of life and reducing treatment burden.
The trial also opens new avenues for designing future studies aimed at cure, guiding how MRD status and remission duration can inform treatment discontinuation strategies and long-term patient management.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
